We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+19.88%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$1.1B
AUM Growth
+$208M
Cap. Flow
+$30.3M
Cap. Flow %
2.77%
Top 10 Hldgs %
54.38%
Holding
136
New
36
Increased
27
Reduced
26
Closed
32

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$35.5M
2
NVO
Novo Nordisk
NVO
+$19.7M
3
URGN icon
UroGen Pharma
URGN
+$12.9M
4
BMY icon
Bristol-Myers Squibb
BMY
+$12.4M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$10.9M

Top Sells

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$19.7M
2
CELG
Celgene Corp
CELG
+$18.8M
3
ITRN icon
Ituran Location and Control
ITRN
+$14.6M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$11.6M
5
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 56.49%
2 Miscellaneous 34.04%
3 Technology 6.57%
4 Consumer Discretionary 1.18%
5 Industrials 1.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
26
Ascendis Pharma A/S
ASND
$15.7B
$8.04M 0.73%
68,273
+10,000
+17% +$876K
SYRE icon
27
Spyre Therapeutics
SYRE
$8.05B
$7.85M 0.72%
39,000
+15,000
+63% +$3.13M
ALLT icon
28
Allot
ALLT
$400M
$7.67M 0.7%
965,931
+370,167
+62% +$2.66M
PANW icon
29
Palo Alto Networks
PANW
$305B
$7.47M 0.68%
184,524
+35,214
+24% +$1.31M
CSTE icon
30
Caesarstone
CSTE
$97.9M
$7.46M 0.68%
478,114
+8,954
+2% +$140K
MSFT icon
31
Microsoft
MSFT
$3.68T
$7.24M 0.66%
61,397
+14,399
+31% +$1.57M
AERI
32
DELISTED
Aerie Pharmaceuticals
AERI
$7.13M 0.65%
+150,000
New +$6.6M
BIIB icon
33
Biogen
BIIB
$32.3B
$7.09M 0.65%
+30,000
New +$9.45M
RETA
34
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$6.99M 0.64%
81,769
-139,500
-63% -$11.6M
ARQL
35
DELISTED
Arqule Inc
ARQL
$6.86M 0.63%
1,432,643
-600,000
-30% -$2.32M
SIOX
36
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$6.79M 0.62%
638,542
-386,458
-38% -$3.85M
IMMU
37
DELISTED
Immunomedics Inc
IMMU
$6.28M 0.57%
326,660
-379,879
-54% -$6.12M
CAMT icon
38
Camtek
CAMT
$6.68B
$6.25M 0.57%
+700,574
New +$5.67M
AUTL
39
Autolus Therapeutics
AUTL
$514M
$6.07M 0.55%
192,994
-10,000
-5% -$284K
KRYS icon
40
Krystal Biotech
KRYS
$9.98B
$5.97M 0.55%
181,625
+7,000
+4% +$165K
TVRD
41
Tvardi Therapeutics
TVRD
$22.4M
$5.96M 0.54%
8,443
– –
GOOGL icon
42
Alphabet (Google) Class A
GOOGL
$4.23T
$5.88M 0.54%
+100,000
New +$5.65M
MYOK
43
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$5.88M 0.54%
+113,000
New +$5.21M
MLNX
44
DELISTED
Mellanox Technologies, Ltd.
MLNX
$5.85M 0.53%
49,394
+21,043
+74% +$2.12M
NEOS
45
DELISTED
Neos Therapeutics, Inc
NEOS
$5.75M 0.52%
2,201,697
– –
XENE icon
46
Xenon Pharmaceuticals
XENE
$5.52B
$5.42M 0.49%
533,655
+84,171
+19% +$714K
AMZN icon
47
Amazon
AMZN
$2.71T
$5.34M 0.49%
+60,000
New +$4.99M
ANAB icon
48
AnaptysBio
ANAB
$1.62B
$5.11M 0.47%
+70,000
New +$4.83M
RCKT icon
49
Rocket Pharmaceuticals
RCKT
$386M
$5.09M 0.46%
290,001
– –
NERV icon
50
Minerva Neurosciences
NERV
$170M
$5.05M 0.46%
80,252
-17,500
-18% -$1.05M
1
2
3 4 5

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q1 2019 Portfolio in Review

As of Q1 2019, Sphera Funds Management held 136 positions worth $1.1B, up 23% from $887M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Sphera Funds Management's Q1 2019 filing shows 36 new, 27 increased, 26 reduced and 32 closed positions. Its largest new stake was Johnson & Johnson: 265,000 shares worth $37M. The largest sale was Viatris, an estimated $19.7M.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 62% a quarter earlier, followed by Miscellaneous and Technology.

  • Sphera Funds Management's largest Q1 2019 buy was Johnson & Johnson: 265,000 shares worth $37M.
  • Sphera Funds Management added most to Bristol-Myers Squibb in Q1 2019, an estimated $12.4M increase.
  • Sphera Funds Management's biggest Q1 2019 reduction was Viatris, cutting an estimated $19.7M.
  • Sphera Funds Management fully exited Ituran Location and Control in Q1 2019, selling an estimated $14.6M.
  • Sphera Funds Management's ten largest holdings make up 54% of its $1.1B portfolio in Q1 2019.
  • Sphera Funds Management opened 36 new positions and closed 32 in Q1 2019.
  • Sphera Funds Management's portfolio value rose 23% quarter-over-quarter to $1.1B.

Based on Sphera Funds Management's 13F filing for Q1 2019, filed 15 May 2019.